Drawing for SCHMITZ SALVE

USPTO serial 87473961

SCHMITZ SALVE

Reviewed by CopyMark Law Group

Reg. 5466516Status 704Registered
Filing date
Status date
Registration date
May 8, 2018
Examiner
CASE, LEIGH CAROLINE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active. Follow Madrid and USPTO deadlines for the next renewal cycle.

Status 704: Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active.

Need help with SCHMITZ SALVE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
003Multipurpose non-medicated salve for humans and animals, including for use with splinter removal, staph and skin infections and wounds, diabetic wounds, diabetic sores, skin burns, insect bites, cuts, scrapes, ingrown hairs and toenails, skin problems, rashes, animal bites, scabs, acne, dry or cracked skin or cuticles, abscesses, boils, inflammation, protecting skin, and promoting the skin healing processACTIVEFeb 27, 2018
035[ Online retail store services featuring multipurpose non-medicated salve for humans and animals, including for use with splinter removal, staph and skin infections and wounds, diabetic wounds, diabetic sores, skin burns, insect bites, cuts, scrapes, ingrown hairs and toenails, skin problems, rashes, animal bites, scabs, acne, dry or cracked skin or cuticles, abscesses, boils, inflammation, protecting skin, and promoting the skin healing process; providing a website featuring consumer purchasing information in the fields of and about the use of salves for humans and animals, including about the use of salves for splinter removal, staph and skin infections and wounds, diabetic wounds, diabetic sores, skin burns, insect bites, cuts, scrapes, ingrown hairs and toenails, skin problems, rashes, animal bites, scabs, acne, dry or cracked skin or cuticles, abscesses, boils, inflammation, protecting skin, and promoting the skin healing process ]SECTION 8 - CANCELLEDNov 1, 2017
044[ Providing a website featuring health and wellness information in the fields of and about the use of salves for humans and animals, including about the use of salves for splinter removal, staph and skin infections and wounds, diabetic wounds, diabetic sores, skin burns, insect bites, cuts, scrapes, ingrown hairs and toenails, skin problems, rashes, animal bites, scabs, acne, dry or cracked skin or cuticles, abscesses, boils, inflammation, protecting skin, and promoting the skin healing process ]SECTION 8 - CANCELLEDNov 1, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 4, 2025WOAGWITHDRAWAL OF ATTORNEY GRANTED
Mar 4, 2025WOARTEAS WITHDRAWAL OF ATTORNEY RECEIVED
Jan 31, 2025NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jan 31, 20258.PRREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Jan 31, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 8, 2024ES8RTEAS SECTION 8 RECEIVED
May 8, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 8, 2018R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Apr 2, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 26, 2018ALIEASSIGNED TO LIE
Mar 17, 2018CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Mar 16, 2018AAUANOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Mar 15, 2018XAECEXAMINER'S AMENDMENT ENTERED
Mar 15, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 15, 2018GNEAEXAMINERS AMENDMENT E-MAILED
Mar 15, 2018CNEAEXAMINERS AMENDMENT -WRITTEN
Mar 15, 2018IUAAUSE AMENDMENT ACCEPTED
Mar 7, 2018AUPCAMENDMENT TO USE PROCESSING COMPLETE
Mar 7, 2018IUAFUSE AMENDMENT FILED
Mar 6, 2018EAAUTEAS AMENDMENT OF USE RECEIVED
Mar 5, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Mar 3, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 3, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 6, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 6, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 6, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 31, 2017DOCKASSIGNED TO EXAMINER
Jun 9, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 6, 2017NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance